Red tape hurt vaccine sales says Serum as it readies new intranasal trivalent flu product
This article was originally published in Scrip
Executive Summary
Serum Institute of India, the world's largest producer of the measles and diphtheria-tetanus-pertussis group of vaccines, is developing an intranasal trivalent influenza vaccine, but claims that government red tape has hurt the prospects of its already launched cut-price, indigenously developed intranasal H1N1 flu vaccine, Nasovac.
You may also be interested in...
Bharat Biotech Plans Coronavirus Vaccine
After two Indian vaccine makers, Serum Institute of India and Cadila Healthcare joined the fight against COVID-19, Bharat Biotech may follow suit. Others like Hilleman have decided against it for the moment while Panacea Biotech is weighing the pros and cons of developing a SARS-CoV-2 vaccine after a sour experience with H1N1.
Evotec, Takeda Execs’ Big Picture Insights To Shape India’s R&D Push
Evotec's CEO and Takeda’s president of R&D provide insights around how India could shape its efforts to accelerate biopharma innovation. Backing the right technologies, fostering a culture to "stop losses" early on for projects that don't work and learning from China’s overhaul of its healthcare system were among the key takeaways.
India’s 'Thousand Talents' Moment And Models To Shift Gears In R&D
Industry leaders including Sanofi's ex-CEO and the chiefs of Sun, Lupin, Glenmark, Dr Reddy’s and Cipla discuss how India could leapfrog its pharma R&D efforts. Could the South Korea model or a hybrid approach including bringing back top talent bolster the country’s efforts to emerge as a global innovation hot spot?